NANTES, FRANCE and CAMBRIDGE, MA--(Marketwire - July 08, 2008) - Vivalis (NYSE Euronext : VLS) announced today that it has granted ACAMBIS INC. (LSE : ACM) rights to the avian embryonic stem cell derived eb66® cell line to evaluate it as a production platform of viral vectors and vaccines.
